Atlas Capital Advisors LLC Acquires 5,178 Shares of Johnson & Johnson (NYSE:JNJ)

Atlas Capital Advisors LLC increased its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 888.2% during the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 5,761 shares of the company’s stock after purchasing an additional 5,178 shares during the period. Atlas Capital Advisors LLC’s holdings in Johnson & Johnson were worth $842,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the business. Lee Danner & Bass Inc. bought a new position in shares of Johnson & Johnson in the 2nd quarter worth $17,750,000. Azzad Asset Management Inc. ADV grew its stake in Johnson & Johnson by 3.6% in the second quarter. Azzad Asset Management Inc. ADV now owns 47,504 shares of the company’s stock valued at $6,943,000 after purchasing an additional 1,664 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its stake in Johnson & Johnson by 20.6% in the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 535,252 shares of the company’s stock valued at $78,232,000 after purchasing an additional 91,423 shares during the last quarter. Stephens Consulting LLC lifted its position in shares of Johnson & Johnson by 4.8% during the second quarter. Stephens Consulting LLC now owns 3,937 shares of the company’s stock valued at $575,000 after buying an additional 180 shares during the last quarter. Finally, Golden State Equity Partners bought a new stake in shares of Johnson & Johnson in the 2nd quarter valued at about $2,182,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on JNJ shares. Daiwa America cut shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. TD Securities decreased their price target on Johnson & Johnson from $195.00 to $185.00 in a research note on Thursday, July 18th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research report on Monday, August 5th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 16th. Finally, Sanford C. Bernstein lifted their price objective on shares of Johnson & Johnson from $161.00 to $171.00 in a research note on Thursday, July 18th. Seven analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $173.21.

Johnson & Johnson Stock Performance

Shares of JNJ traded up $1.63 during mid-day trading on Friday, reaching $165.86. The company had a trading volume of 7,441,042 shares, compared to its average volume of 7,271,470. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $165.98. The stock has a 50 day moving average of $155.34 and a two-hundred day moving average of $153.45. The stock has a market capitalization of $399.17 billion, a P/E ratio of 10.34, a PEG ratio of 2.63 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The business had revenue of $22.45 billion for the quarter, compared to analyst estimates of $22.33 billion. During the same period in the prior year, the company posted $2.80 EPS. The company’s revenue for the quarter was up 4.3% on a year-over-year basis. On average, analysts expect that Johnson & Johnson will post 10.07 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th will be given a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, August 27th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 2.99%. Johnson & Johnson’s dividend payout ratio (DPR) is 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.